Baird analyst Colleen Kusy raised the firm’s price target on Apellis (APLS) to $50 from $47 and keeps an Outperform rating on the shares. The firm updated its model ahead of Q2 earnings while noting a competitor’s product to Syfovre is nearing C3G approval.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target raised to $24 from $23 at BofA
- Apellis Pharmaceuticals: Strong Market Position and Growth Potential Justify Buy Rating
- Apellis Pharmaceuticals: Sustained Growth Potential and Market Resilience Justify Buy Rating
- Apellis price target raised to $26 from $25 at Morgan Stanley
- Cautious Optimism: Apellis Pharmaceuticals’ Strategic Moves and Market Uncertainties Justify Hold Rating